Matthias Kleinz

Novasenta develops treatments to transform the lives of patients with cancer. It uses systematic, rigorous, and unbiased human tumor microenvironment analysis to uncover new druggable targets, exploiting the critical interplay of disease, immune response, and metabolism. Single-cell level analysis of high-quality, human tumor samples combined withthe advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient. The company aims to identify novel targets to generate effective therapies for various cancers. It was founded in 2018 and is headquartered in Pittsburgh, Pennsylvania.